Title |
Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response
|
---|---|
Published in |
Virology Journal, July 2013
|
DOI | 10.1186/1743-422x-10-229 |
Pubmed ID | |
Authors |
Nir Paran, Shlomo Lustig, Anat Zvi, Noam Erez, Tomer Israely, Sharon Melamed, Boaz Politi, David Ben-Nathan, Paula Schneider, Batel Lachmi, Ofir Israeli, Dana Stein, Reuven Levin, Udy Olshevsky |
Abstract |
Vaccinia virus protein A33 (A33VACV) plays an important role in protection against orthopoxviruses, and hence is included in experimental multi-subunit smallpox vaccines. In this study we show that single-dose vaccination with recombinant Sindbis virus expressing A33VACV, is sufficient to protect mice against lethal challenge with vaccinia virus WR (VACV-WR) and ectromelia virus (ECTV) but not against cowpox virus (CPXV), a closely related orthopoxvirus. Moreover, a subunit vaccine based on the cowpox virus A33 ortholog (A33CPXV) failed to protect against cowpox and only partially protected mice against VACV-WR challenge. We mapped regions of sequence variation between A33VACV and A33CPXVand analyzed the role of such variations in protection. We identified a single protective region located between residues 104-120 that harbors a putative H-2Kd T cell epitope as well as a B cell epitope - a target for the neutralizing antibody MAb-1G10 that blocks spreading of extracellular virions. Both epitopes in A33CPXV are mutated and predicted to be non-functional. Whereas vaccination with A33VACV did not induce in-vivo CTL activity to the predicted epitope, inhibition of virus spread in-vitro, and protection from lethal VACV challenge pointed to the B cell epitope highlighting the critical role of residue L118 and of adjacent compensatory residues in protection. This epitope's critical role in protection, as well as its modifications within the orthopoxvirus genus should be taken in context with the failure of A33 to protect against CPXV as demonstrated here. These findings should be considered when developing new subunit vaccines and monoclonal antibody based therapeutics against orthopoxviruses, especially variola virus, the etiologic agent of smallpox. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
China | 1 | 5% |
Unknown | 21 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 27% |
Student > Bachelor | 3 | 14% |
Researcher | 2 | 9% |
Student > Doctoral Student | 1 | 5% |
Other | 1 | 5% |
Other | 2 | 9% |
Unknown | 7 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 18% |
Agricultural and Biological Sciences | 4 | 18% |
Biochemistry, Genetics and Molecular Biology | 3 | 14% |
Immunology and Microbiology | 2 | 9% |
Mathematics | 1 | 5% |
Other | 3 | 14% |
Unknown | 5 | 23% |